Which has preferable valuation and earnings, IVA or ARTV?

Artiva Biotherapeutics has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 160.19 -$400.67M N/A N/A Artiva Biotherapeutics $250K 672.38 -$83.86M -$3.54 N/A

Is IVA or ARTV more profitable?

Inventiva's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Artiva Biotherapeutics N/A -73.15% -62.74%

Does the media prefer IVA or ARTV?

In the previous week, Inventiva had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.67 beat Inventiva's score of 0.36 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLMD or ARTV more profitable?

Relmada Therapeutics' return on equity of -71.22% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Artiva Biotherapeutics N/A -73.15% -62.74%

Is ARTV or ANRO more profitable?

Alto Neuroscience's return on equity of -47.22% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -73.15% -62.74% Alto Neuroscience N/A -47.22% -38.81%

Is ARTV or ALLO more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -73.15% -62.74% Allogene Therapeutics N/A -56.45% -40.36%

Does the media refer more to ARTV or ALLO?

In the previous week, Allogene Therapeutics had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.67 beat Allogene Therapeutics' score of 0.65 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARTV or BIOA?

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 2 mentions for BioAge Labs. Artiva Biotherapeutics' average media sentiment score of 0.67 beat BioAge Labs' score of -1.08 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Artiva Biotherapeutics (ARTV) Competitors

$6.80 -0.05 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$6.82 +0.02 (+0.22%)

As of 07:50 PM Eastern

Compare

ARTV vs. IVA, RLMD, ANRO, ALLO, and BIOA

Should you buy Artiva Biotherapeutics stock or one of its competitors? MarketBeat compares Artiva Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artiva Biotherapeutics include Inventiva (IVA), Relmada Therapeutics (RLMD), Alto Neuroscience (ANRO), Allogene Therapeutics (ALLO), and BioAge Labs (BIOA). These companies are all part of the "pharmaceutical products" industry.

How does Artiva Biotherapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Inventiva's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Artiva Biotherapeutics	N/A	-73.15%	-62.74%

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 323.42%. Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 473.53%. Given Artiva Biotherapeutics' higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Inventiva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

19.1% of Inventiva shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Artiva Biotherapeutics has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	160.19	-$400.67M	N/A	N/A
Artiva Biotherapeutics	$250K	672.38	-$83.86M	-$3.54	N/A

In the previous week, Inventiva had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.67 beat Inventiva's score of 0.36 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market.

Summary

Inventiva beats Artiva Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 0 mentions for Relmada Therapeutics. Artiva Biotherapeutics' average media sentiment score of 0.67 beat Relmada Therapeutics' score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Relmada Therapeutics	Neutral
Artiva Biotherapeutics	Positive

45.2% of Relmada Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Relmada Therapeutics' return on equity of -71.22% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Artiva Biotherapeutics	N/A	-73.15%	-62.74%

Relmada Therapeutics has higher earnings, but lower revenue than Artiva Biotherapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Artiva Biotherapeutics	$250K	672.38	-$83.86M	-$3.54	N/A

Relmada Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 109.79%. Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 473.53%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Relmada Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market.

Summary

Artiva Biotherapeutics beats Relmada Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Alto Neuroscience?

Artiva Biotherapeutics (NASDAQ:ARTV) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Artiva Biotherapeutics presently has a consensus target price of $39.00, indicating a potential upside of 473.53%. Alto Neuroscience has a consensus target price of $35.25, indicating a potential upside of 93.14%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Alto Neuroscience's return on equity of -47.22% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Alto Neuroscience	N/A	-47.22%	-38.81%

Alto Neuroscience has lower revenue, but higher earnings than Artiva Biotherapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	672.38	-$83.86M	-$3.54	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Alto Neuroscience. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 0 mentions for Alto Neuroscience. Artiva Biotherapeutics' average media sentiment score of 0.67 beat Alto Neuroscience's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Artiva Biotherapeutics	Positive
Alto Neuroscience	Neutral

Artiva Biotherapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Summary

Artiva Biotherapeutics beats Alto Neuroscience on 8 of the 13 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Allogene Therapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Artiva Biotherapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Artiva Biotherapeutics presently has a consensus price target of $39.00, indicating a potential upside of 473.53%. Allogene Therapeutics has a consensus price target of $8.52, indicating a potential upside of 360.66%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Artiva Biotherapeutics is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

83.6% of Allogene Therapeutics shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Allogene Therapeutics had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.67 beat Allogene Therapeutics' score of 0.65 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artiva Biotherapeutics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	672.38	-$83.86M	-$3.54	N/A
Allogene Therapeutics	$20K	31,926.38	-$190.89M	-$0.77	N/A

Allogene Therapeutics' return on equity of -56.45% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

Artiva Biotherapeutics beats Allogene Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to BioAge Labs?

Artiva Biotherapeutics (NASDAQ:ARTV) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Artiva Biotherapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
BioAge Labs	-871.75%	-29.40%	-27.26%

BioAge Labs has higher revenue and earnings than Artiva Biotherapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	672.38	-$83.86M	-$3.54	N/A
BioAge Labs	$8.99M	76.69	-$80.61M	-$2.40	N/A

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 2 mentions for BioAge Labs. Artiva Biotherapeutics' average media sentiment score of 0.67 beat BioAge Labs' score of -1.08 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 473.53%. BioAge Labs has a consensus price target of $43.50, indicating a potential upside of 180.46%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Artiva Biotherapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Artiva Biotherapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Summary

Artiva Biotherapeutics beats BioAge Labs on 9 of the 15 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTV vs. The Competition

Export

Metric	Artiva Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$169.31M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-1.92	18.61	23.92	23.74
Price / Sales	672.38	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.52	8.04	10.28	6.78
Net Income	-$83.86M	$23.89M	$3.57B	$337.51M
7 Day Performance	-8.85%	-5.97%	-1.43%	-2.72%
1 Month Performance	-37.56%	2.78%	3.27%	1.87%
1 Year Performance	223.81%	36.26%	23.37%	26.60%

Artiva Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTV Artiva Biotherapeutics	4.2401 of 5 stars	$6.80 -0.7%	$39.00 +473.5%	+226.2%	$169.31M	$250K	N/A	81	Analyst Forecast Gap Up
IVA Inventiva	3.567 of 5 stars	$5.16 +1.8%	$16.56 +220.8%	+14.5%	$753.10M	$5.07M	N/A	100
RLMD Relmada Therapeutics	1.6098 of 5 stars	$7.17 +1.8%	$12.00 +67.4%	+612.7%	$752.06M	N/A	N/A	10
ANRO Alto Neuroscience	1.8409 of 5 stars	$21.08 -0.7%	$35.25 +67.2%	+614.1%	$739.70M	N/A	N/A	N/A
ALLO Allogene Therapeutics	2.9109 of 5 stars	$2.12 +6.0%	$8.52 +302.0%	+32.4%	$731.72M	$20K	N/A	310	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTV) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. IVA, RLMD, ANRO, ALLO, and BIOA

How does Artiva Biotherapeutics compare to Inventiva?

Summary

How does Artiva Biotherapeutics compare to Relmada Therapeutics?

Summary

How does Artiva Biotherapeutics compare to Alto Neuroscience?

Summary

How does Artiva Biotherapeutics compare to Allogene Therapeutics?

Summary

How does Artiva Biotherapeutics compare to BioAge Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. IVA, RLMD, ANRO, ALLO, and BIOA

How does Artiva Biotherapeutics compare to Inventiva?

Is IVA or ARTV more profitable?

Do analysts recommend IVA or ARTV?

Do institutionals and insiders believe in IVA or ARTV?

Which has preferable valuation and earnings, IVA or ARTV?

Does the media prefer IVA or ARTV?

Which has more volatility and risk, IVA or ARTV?

Summary

How does Artiva Biotherapeutics compare to Relmada Therapeutics?

Does the media favor RLMD or ARTV?

Do institutionals and insiders believe in RLMD or ARTV?

Is RLMD or ARTV more profitable?

Which has stronger valuation and earnings, RLMD or ARTV?

Do analysts rate RLMD or ARTV?

Which has more risk & volatility, RLMD or ARTV?

Summary

How does Artiva Biotherapeutics compare to Alto Neuroscience?

Do analysts recommend ARTV or ANRO?

Is ARTV or ANRO more profitable?

Which has better earnings & valuation, ARTV or ANRO?

Does the media refer more to ARTV or ANRO?

Which has more volatility & risk, ARTV or ANRO?

Summary

How does Artiva Biotherapeutics compare to Allogene Therapeutics?

Which has more volatility & risk, ARTV or ALLO?

Do analysts prefer ARTV or ALLO?

Do insiders & institutionals believe in ARTV or ALLO?

Does the media refer more to ARTV or ALLO?

Which has preferable valuation and earnings, ARTV or ALLO?

Is ARTV or ALLO more profitable?

Summary

How does Artiva Biotherapeutics compare to BioAge Labs?

Is ARTV or BIOA more profitable?

Which has better valuation and earnings, ARTV or BIOA?

Does the media prefer ARTV or BIOA?

Do analysts recommend ARTV or BIOA?

Which has more risk & volatility, ARTV or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools